187
Views
85
CrossRef citations to date
0
Altmetric
Original Article

Role of AP-1 and HIF-1 Transcription Factors in TGF-β Activation of VEGF Expression

&
Pages 19-34 | Received 16 Oct 2000, Accepted 02 Jan 2001, Published online: 11 Jul 2009
 

Abstract

Aberrant expression of vascular endothelial growth factor (VEGF) has been demonstrated to be associated with most human solid tumors. Here we report that TGF-β potently induces VEGF expression in human HT-1080 fibrosarcomas primarily through transcrip-tional activation with no significant changes in mRNA turnover. The tyrosine kinase inhibitor genistein and AP-1 inhibitor curcumin significantly blocked TGF-β induction of VEGF expression while SP-1 and MKKl inhibitors did not. TGF-β enhanced both AP-1 and HIF-1 DNA binding activities whereas SP-1, AP-2 and NF-1 did not show major changes. Transcriptional reporter assays provided further evidence that TGF-β augmented both AP-1 and HIF-1 activities. Moreover, TGF-β-treated HT-1080 cells contained higher levels of HIF-1α and c-jun proteins in nuclear extracts. TGF-β and hypoxia synergistically induced VEGF mRNA expression. Given the fact that most tumors respond to hypoxic stress with increased VEGF expression via HIF-1 dependent transcription, this study identifies for the fmt time that TGF-β also increases VEGF mRNA in an AP-l/HIF-1-dependent mechanism and may potentiate the hypoxic response.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.